
The ICON Cares 2025 Report is now live. Sharing progress across clinical research people, communities and ESG priorities. Read more: ow.ly/WHo650ZF35Q #ICONCares #ESG #ClinicalResearch #Sustainability #SDG3

Global provider of Outsourced Clinical Research

The ICON Cares 2025 Report is now live. Sharing progress across clinical research people, communities and ESG priorities. Read more: ow.ly/WHo650ZF35Q #ICONCares #ESG #ClinicalResearch #Sustainability #SDG3

Speed matters in obesity development. So does keeping participants engaged. Explore practical strategies for balancing study acceleration with retention in our on-demand webinar. Watch now: ow.ly/LtUN51056PI

ADC eligibility has long relied on a binary antigen call — positive or negative. But this may not capture the expression gradations that influence response. Explore why antigen expression may need to be treated as a continuous biomarker. ow.ly/tygz5104YK4

Even the most scientifically elegant protocol will fail if chronic disease patients find the trial burden unmanageable. Learn how early collaboration with patient organisations helps sponsors design feasible, patient-centred trials in our whitepaper: ow.ly/PBzk5103mu8

Use an existing #COA instrument or develop a new one? Watch ICON and Mapi Research Trust discuss the evidence and considerations behind fit-for-purpose instrument selection. ow.ly/brmv5106llX #COA #ClinicalTrials #RegulatoryStrategy

We are pleased to be included on TIME’s World’s Most Impactful Companies 2026 list. This recognition reflects the dedication of our colleagues and partners advancing clinical research and improving patient outcomes worldwide. ow.ly/5CoW50ZVT7X #ICONCares #COP31

ICON supports #WorldDiabetesDay. From Type 1 & Type 2 diabetes, adult to pediatric populations—we’ve conducted 187metabolic trials, including 51 focused on diabetes. Learn more. #WorldDiabetesDay ow.ly/A3lJ5105YcT

With #WorldDiabetesDay approaching, what’s next for metabolic R&D? Explore how evolving GLP-1 strategies, new mechanisms and broader endpoints are shaping diabetes and obesity drug development. ow.ly/YPFy5105Ycg

Heading to the 19th EBF Open Symposium in Barcelona? ICON will be there from 17–19 November at the Hyatt Regency Barcelona Tower. Stop by booth B1 to explore how our bioanalytical services help bring therapies to market with speed and scientific rigor. ow.ly/I8S0510043w

As biosimilar pathways evolve, success for innovator companies will increasingly depend on differentiation rather than exclusivity. Read insights from ICON. ow.ly/TOli5102kSa #Biosimilars #DrugDevelopment

Sponsors need regulatory partners that combine expertise, broad capabilities and global delivery. ICON has been named a Leader in the Everest Group Life Sciences Regulatory Affairs Services PEAK Matrix® Assessment 2026. Read more ow.ly/7px750ZWatJ

Meet us at #ObesityWeek, Nov 14–17, booth 212 to discuss how ICON uses real-world evidence to uncover prescriber behavior, payer influence & patient needs—identifying subpopulations & quantifying impact to build stronger value. ow.ly/qJ0J50ZZhxf

When Congress deadlines, extension and notifications dates change, will you know? PubsHub Journals & Congresses incorporates user-defined watchlists that can send alerts in the case of deadline updates, extensions and other changes. ow.ly/NSoF50ZEows

Regulatory pathways for immunotherapies outside oncology are evolving, with differing regional expectations between the US and EU. Gain insights into navigating shifting requirements, accelerated pathways, and indication selection in the whitepaper: ow.ly/GKnT50ZTuE2

The 2024 accelerated approval of trastuzumab deruxtecan as the first tumor-agnostic ADC signals that pan-cancer development is within reach. Expanding access across diverse histologies, however, will require more precise patient selection. Read more. ow.ly/LQ1J5104YHt

Biomarker-based enrolment can compress early-intervention trial timelines, but it can also exclude patients a therapy is meant to help. The precision–inclusivity trade-off is critical in early chronic disease development. Explore the implications. ow.ly/gZqq5102TTO